Recently, one of the biggest biotech dividend stocks, PDL BioPharma (Nasdaq: PDLI), announced that its CFO has left the company for "personal reasons." While investors are always wary of management shakeups, this move had little effect on the company's share price.

In the following video, health-care analysts Max Macaluso and Brenton Flynn discuss this move and one issue PDL BioPharma investors must continue to keep a close eye on.

Brenton Flynn and Max Macaluso, Ph.D., have no positions in the stocks mentioned above. The Motley Fool owns shares of PDL BioPharma. Motley Fool newsletter services recommend Biogen Idec, Elan, and PDL BioPharma. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.